Search Results - "Subcutaneous infusions"

Observational Retrospective Cohort of Patient Support Program Data on Practical Experiences of Treatment with Foslevodopa/Foscarbidopa in Advanced Parkinson’s Disease: The ORCHESTRA Study.

Authors: Warnecke, Tobias Van der Plas, Anton Adriaan Schwingenschuh, Petra et al.

Source: Neurology & Therapy. Jun2026, p1-23. 23p.

Real-World Safety and Effectiveness of 24-Hour Foslevodopa/Foscarbidopa in Parkinson's Disease: ROSSINI Study 6-Month Interim Results.

Authors: Jost, Wolfgang H. Bergquist, Filip Evans, Andrew et al.

Source: Neurology & Therapy. May2026, p1-20. 20p.

Patient Experience and Improvement Opportunities in Self-Administered, Large-Volume Subcutaneous Infusions at Home.

Authors: Franzese, Chris Hawthorne, James Katsaros, Dimos et al.

Source: Patient Preference & Adherence. Aug2025, Vol. 19, p2459-2491. 33p.

Sustained metabolic reduction and hypothermia in humans.

Authors: Flickinger, Katharyn L. Weissman, Alexandra J. Guyette, Francis X. et al.

Source: PLoS ONE. 4/21/2025, Vol. 20 Issue 4, p1-15. 15p.

Subcutaneous Lidocaine Infusion for Chronic Widespread Pain: A Chart Review and Survey Examining the Safety and Tolerability of Treatment.

Authors: Gregoire, Nina Kaseweter, Kimberley Klukas, Ethan et al.

Source: Journal of Clinical Medicine. Apr2025, Vol. 14 Issue 7, p2440. 10p.

Preclinical Safety Evaluation of BB106, a Novel Ketamine–Sulfobutylether-Beta-Cyclodextrin Salt, Following Subcutaneous Administration in Rats and Göttingen Minipigs.

Authors: Ramot, Yuval Andreini, Isabella Sacco, Giuseppe et al.

Source: International Journal of Toxicology (Sage). May/Jun2026, Vol. 45 Issue 3, p232-246. 15p.

Feasibility and pharmacokinetic evaluation of a needle‐free injector for delivering high concentration antibody formulations.

Authors: Josowitz, Alexander Manoj, Arjun Sree Laiacona, Danielle et al.

Source: Bioengineering & Translational Medicine; May2026, Vol. 11 Issue 3, p1-13, 13p

Peripheral Neuropathy during Subcutaneous Foslevodopa/Foscarbidopa Infusion in Parkinson's Disease: A Case Series.

Authors: Vial‐Daragon, Lucie Poncet‐Megemont, Louis Derost, Philippe et al.

Source: Movement Disorders Clinical Practice. Apr2026, p1. 6p.

Foslevodopa+foscarbidopa for advanced Parkinson disease.

Source: Australian Prescriber. Apr2026, Vol. 49 Issue 2, p74-75. 2p.

Customizing Parkinson's care: sustaining continuous levodopa therapy post-gastrectomy.

Authors: Buonocore, Jolanda Ammendola, Michele Romano, Roberto et al.

Source: Neurological Sciences. Jul2025, Vol. 46 Issue 7, p3315-3317. 3p.

Subjects: Percutaneous endoscopic gastrostomy, Parkinson's disease, Gastric emptying, Subcutaneous infusions, Infusion therapy, Gastric bypass, Jejunoileal bypass

Patient Preferences for Faster Home-Based Subcutaneous Immunoglobulin Infusion Therapy and the Effect on Adverse Events.

Authors: Rutland, Brent Southworth, Carleton Bosshard, Jasmin

Source: Patient Preference & Adherence. Mar2025, Vol. 18, p615-621. 7p.

Continuous, subcutaneous apomorphine infusion for Parkinson disease motor fluctuations: Results from the phase 3, long-term, open-label United States InfusON study.

Authors: Isaacson, Stuart H Espay, Alberto J Pahwa, Rajesh et al.

Source: Journal of Parkinson's Disease. Mar2025, Vol. 15 Issue 2, p361-373. 13p.

Device-assisted therapies for Parkinson disease.

Authors: Mouchaileh, Nadia Cameron, Jillian

Source: Australian Prescriber. Feb2025, Vol. 48 Issue 1, p10-17. 8p.

Paeoniflorin Inhibits Atrial Fibrosis and Atrial Fibrillation in Angiotensin II-Infused Mice Through the PI3K-Akt Pathway.

Authors: Ji, Yaqiong Ning, Zhongping

Source: Dose-Response. Oct-Dec2024, Vol. 22 Issue 4, p1-13. 13p.

Model-based steady state pharmacokinetic predictions using high throughput cassette infusion approach in mice.

Authors: Daripelli, Saivishal Raje, Amol Achyutrao Kandikere, Vishwottam et al.

Source: Xenobiotica. Mar2026, Vol. 56 Issue 3, p204-213. 10p.

Continuous Subcutaneous Versus Intestinal Levodopa Infusion for Parkinson's Disease: A Real‐World, Monocentric, Observational Study and Critical Review.

Authors: Hartig, Johannes Sitzmann, Lennert Hartenstein, Doreen et al.

Source: Movement Disorders Clinical Practice. Feb2026, p1. 11p. 3 Illustrations.

Resolution of Levodopa/Dopa‐Decarboxylase Inhibitor—Associated Microscopic Colitis with Subcutaneous Foslevodopa/Foscarbidopa: A Case Series and Review of the Literature.

Authors: Hintner, Romana Eberhardt, Franziska Kofler, Manuela et al.

Source: Movement Disorders Clinical Practice. Feb2026, p1. 10p. 2 Illustrations.

Subcutaneous Levodopa in Parkinson's Disease: A Systematic Review and Meta‐Analysis.

Authors: Burton, Matthew Marsden, Duncan Harish, Dhruv et al.

Source: European Journal of Neurology. Feb2026, Vol. 33 Issue 2, p1-14. 14p.

Subjects: Subcutaneous infusions, Parkinson's disease, Quality of life, Dopa, Drug side effects

Switching from Levodopa/Carbidopa Intestinal Gel to Continuous Subcutaneous Foslevodopa/Carbidopa Infusion in Advanced Parkinson's Disease: A Case Series.

Authors: Baille, Guillaume Patte‐Karsenti, Nathalie Salardaine, Quentin et al.

Source: Movement Disorders Clinical Practice. Feb2026, Vol. 13 Issue 2, p521-527. 7p.

Perfusion sous-cutanée : indications, modalités et tolérance.

Authors: Arcani, Robin George, Julia Correard, Florian et al.

Source: Revue de Médecine Interne. Feb2026, Vol. 47 Issue 2, p76-83. 8p.